HeartBeam Inc. (NASDAQ: BEAT) announced the launch of a pilot study focused on evaluating its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia. This study represents a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam's technology aims to address this critical need.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand…
The study evaluates the patch's ability to detect inadequate blood flow and oxygen supply to tissue, or ischemia, a key indicator of coronary artery disease. If successful, the HeartBeam patch could offer a non-invasive, convenient solution for continuous cardiac monitoring, enabling earlier detection and intervention.
HeartBeam's technology is designed to provide clinical-grade electrocardiogram data on demand, which could significantly enhance the management of patients with known or suspected coronary artery disease. The pilot study will assess the patch's performance in detecting ischemic episodes, potentially paving the way for broader clinical adoption.
The latest news and updates relating to BEAT are available in the company’s newsroom at https://nnw.fm/BEAT.
